Literature DB >> 18981372

Weight loss in Huntington disease increases with higher CAG repeat number.

N A Aziz1, J M M van der Burg, G B Landwehrmeyer, P Brundin, T Stijnen, R A C Roos.   

Abstract

OBJECTIVE: Huntington disease (HD) is a hereditary neurodegenerative disorder caused by an expanded number of CAG repeats in the huntingtin gene. A hallmark of HD is unintended weight loss, the cause of which is unknown. In order to elucidate the underlying mechanisms of weight loss in HD, we studied its relation to other disease characteristics including motor, cognitive, and behavioral disturbances and CAG repeat number.
METHODS: In 517 patients with early stage HD, we applied mixed-effects model analyses to correlate weight changes over 3 years to CAG repeat number and various components of the Unified Huntington's Disease Rating Scale (UHDRS). We also assessed the relation between CAG repeat number and body weight and caloric intake in the R6/2 mouse model of HD.
RESULTS: In patients with HD, mean body mass index decreased with -0.15 units per year (p < 0.001). However, no single UHDRS component, including motor, cognitive, and behavioral scores, was independently associated with the rate of weight loss. Patients with HD with a higher CAG repeat number had a faster rate of weight loss. Similarly, R6/2 mice with a larger CAG repeat length had a lower body weight, whereas caloric intake increased with larger CAG repeat length.
CONCLUSIONS: Weight loss in Huntington disease (HD) is directly linked to CAG repeat length and is likely to result from a hypermetabolic state. Other signs and symptoms of HD are unlikely to contribute to weight loss in early disease stages. Elucidation of the responsible mechanisms could lead to effective energy-based therapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981372     DOI: 10.1212/01.wnl.0000334276.09729.0e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  92 in total

1.  Weight changes in subthalamic nucleus vs globus pallidus internus deep brain stimulation: results from the COMPARE Parkinson disease deep brain stimulation cohort.

Authors:  Maren C Locke; Samuel S Wu; Kelly D Foote; Marco Sassi; Charles E Jacobson; Ramon L Rodriguez; Hubert H Fernandez; Michael S Okun
Journal:  Neurosurgery       Date:  2011-05       Impact factor: 4.654

Review 2.  Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission.

Authors:  P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2014-03-28       Impact factor: 7.851

3.  Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.

Authors:  Brett D Dufour; Catherine A Smith; Randall L Clark; Timothy R Walker; Jodi L McBride
Journal:  Mol Ther       Date:  2014-01-06       Impact factor: 11.454

4.  Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease.

Authors:  Karen Marder; Yian Gu; Shirley Eberly; Caroline M Tanner; Nikolaos Scarmeas; David Oakes; Ira Shoulson
Journal:  JAMA Neurol       Date:  2013-11       Impact factor: 18.302

5.  Fat-free mass and its predictors in Huntington's disease.

Authors:  S D Süssmuth; V M Müller; C Geitner; G B Landwehrmeyer; S Iff; A Gemperli; Michael Orth
Journal:  J Neurol       Date:  2015-04-23       Impact factor: 4.849

6.  Upper gastrointestinal findings in Huntington's disease: patients suffer but do not complain.

Authors:  Jürgen E Andrich; Michael Wobben; Peter Klotz; Oliver Goetze; Carsten Saft
Journal:  J Neural Transm (Vienna)       Date:  2009-09-22       Impact factor: 3.575

7.  Force-plate quantification of progressive behavioral deficits in the R6/2 mouse model of Huntington's disease.

Authors:  Stephen C Fowler; Benjamin R Miller; Thomas W Gaither; Michael A Johnson; George V Rebec
Journal:  Behav Brain Res       Date:  2009-03-28       Impact factor: 3.332

8.  Study of plasma-derived miRNAs mimic differences in Huntington's disease brain.

Authors:  Andrew G Hoss; Valentina N Lagomarsino; Samuel Frank; Tiffany C Hadzi; Richard H Myers; Jeanne C Latourelle
Journal:  Mov Disord       Date:  2015-11-17       Impact factor: 10.338

9.  Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease.

Authors:  Claudia Rose; Fiona M Menzies; Maurizio Renna; Abraham Acevedo-Arozena; Silvia Corrochano; Oana Sadiq; Steve D Brown; David C Rubinsztein
Journal:  Hum Mol Genet       Date:  2010-02-27       Impact factor: 6.150

10.  Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.

Authors:  Hilary Moffitt; Graham D McPhail; Ben Woodman; Carl Hobbs; Gillian P Bates
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.